Search Results

Eric Trinquet —how structured play turns into assays and why serendipity belongs in your build process

Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights

Prioritize assays based on project phase and decision points Map go/no-go logic that guides program momentum they’ll change outcomes No More Strategy Swirl I build structure that sticks—from CRO engagement to assay

To stay relevant in the next decade, it’s not about chasing the latest assay or tool.

clear expectations and deliverables to build trust and reduce delays • Align teams across roles—from assay Decisions—Not Delays I help turn great science into clear deliverables • Define program objectives and guide assay

His current work is mainly focused on screening and assay development to bridge the gap between in vitro

the human aGPCRs CD97/ADGRE5 and Latrophilin/ADGRL3 and tested in HEK293T cells using a luciferase assay Tobias Langenhan's group, where I currently manage a project to establish a drug screening assay for In addition, the platform was used to develop assays for high-throughput screening for challenging adhesion

There she researched the beta-2 adrenergic receptor and developed assays to investigate real-time activity

In this AMA session, you’ll learn how to: Decode GPCR signaling complexity using functional assay strategies

GPCR Podcast Read full article Back when GPCR assays were performed with single channel pipettes, failure Michelle Halls still remembers pipetting one sample at a time, holding her breath to keep the assay alive To stay relevant in the next decade, it’s not about chasing the latest assay or tool. receptor-ligand interactions after the fact; they aim to forecast receptor behavior before the first assay Eric Trinquet —how structured play turns into assays and why serendipity belongs in your build process

his work on bioluminescence resonance energy transfer (BRET) resulted in the development of screening assays

Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the first adenosine receptor binding assay

out of the GAIN domain or by being partially exposed, however the recent TA-bound 7TM structures of multiple for receptor activator and continuously work to identify novel chemical modulators of AGPCRs through assay I have previous work experience at two separate contract research organizations centered on assay development

his work on bioluminescence resonance energy transfer (BRET) resulted in the development of screening assays

, to exploit a Ric-8-based technology to purify recombinant G proteins and to use the G proteins in assays

From Pipettes to Platforms: The Evolution of GPCR Research The first time Michelle ran a cyclic AMP assay

From Pipettes to Platforms: The Evolution of GPCR Research The first time Michelle ran a cyclic AMP assay

- Quantifying agonist pharmacology and biased agonism Class 3 - Antagonist pharmacology and binding assay the Optimization of Candidate Selection Lecture 1: The Eyes to See- The Importance of Pharmacologic Assays

the Forefront of GPCR Drug Discovery Gain insider methods from the pioneers shaping biased signaling, assay Pharmechanics GPCR signaling & biased agonism expert regularly consulted by top pharma companies for assay Weekly GPCR Insights (papers, jobs, events) Networking with a global scientist community One failed assay

Issue Oct 17 - 23, 2025 Enzyme Insight, Real-World Impact Read Full Issue Oct 10 - 16, 2025 Design Assays

From Pipettes to Platforms: The Evolution of GPCR Research The first time Michelle ran a cyclic AMP assay

From Pipettes to Platforms: The Evolution of GPCR Research The first time Michelle ran a cyclic AMP assay

Despite the availability of modern tools, Ben stresses the enduring value of classical methods like GTPγS assays Using site-directed mutagenesis and pharmacological synergy assays , his team aims to understand how

I employ a multidisciplinary approach that combines molecular pharmacology, biochemical assays, and biophysical

Translate project strategy into clear decision-driving assays Eliminate “nice to have” tests that stall

predict invasive potential of a luminal breast carcinoma we will (a) determine, via loss-of-function assays on ADGRL3, where I conducted research involving mammalian cell cultures and techniques such as BRET assays and gene expression assays.

research focuses on elucidating the molecular basis of membrane protein signalling using quantitative assays

Sokhom recalls how binding assays at BMS introduced him to the depth and complexity of receptor pharmacology

these studies highlight the possibility that tissue expression of single aGPCRs is likely comprised of multiple Detection of transcripts that do, and do not, contain multiple variable regions suggests expression of multiple mRNAs in specific cells. This research focuses on the design of a new endogenous ADGRB1 activation reporter assay to test analogs

Premium Members Include: ✔ Drug hunters at early-stage biotechs ✔ CRO leaders building assays and tools